Zacks: Analysts Expect Esperion Therapeutics, Inc. (NASDAQ:ESPR) Will Post Earnings of -$0.95 Per Share

Brokerages forecast that Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Rating) will post ($0.95) earnings per share for the current quarter, according to Zacks. Five analysts have made estimates for Esperion Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.98) and the highest estimate coming in at ($0.88). Esperion Therapeutics reported earnings of ($1.67) per share in the same quarter last year, which would indicate a positive year over year growth rate of 43.1%. The company is expected to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Esperion Therapeutics will report full-year earnings of ($3.73) per share for the current year, with EPS estimates ranging from ($3.94) to ($3.50). For the next financial year, analysts expect that the firm will post earnings of ($2.05) per share, with EPS estimates ranging from ($3.10) to $0.15. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for Esperion Therapeutics.

Esperion Therapeutics (NASDAQ:ESPR – Get Rating) last released its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.11. The company had revenue of $18.84 million for the quarter, compared to analyst estimates of $15.41 million. Esperion Therapeutics’s revenue for the quarter was up 136.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($3.50) earnings per share.

A number of research firms recently issued reports on ESPR. HC Wainwright began coverage on shares of Esperion Therapeutics in a research report on Thursday, March 10th. They set a “buy” rating and a $22.00 price objective for the company. JPMorgan Chase & Co. upgraded shares of Esperion Therapeutics from an “underweight” rating to a “neutral” rating and set a $6.00 price target for the company in a research report on Wednesday, May 4th. Credit Suisse Group decreased their price target on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “neutral” rating for the company in a research report on Friday, January 14th. Finally, StockNews.com initiated coverage on shares of Esperion Therapeutics in a research report on Thursday, March 31st. They issued a “sell” rating for the company. Three analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Esperion Therapeutics has a consensus rating of “Hold” and a consensus price target of $21.11.

ESPR stock traded up $0.54 during trading on Friday, reaching $5.78. 1,277,868 shares of the company were exchanged, compared to its average volume of 1,651,839. The company has a 50-day moving average of $5.25 and a two-hundred day moving average of $5.54. Esperion Therapeutics has a twelve month low of $3.28 and a twelve month high of $26.77.

Large investors have recently bought and sold shares of the company. Denali Advisors LLC bought a new stake in shares of Esperion Therapeutics in the 1st quarter valued at $49,000. Principal Financial Group Inc. bought a new stake in shares of Esperion Therapeutics in the 1st quarter valued at $49,000. ProShare Advisors LLC bought a new position in Esperion Therapeutics during the fourth quarter worth $50,000. Spire Wealth Management bought a new position in Esperion Therapeutics during the fourth quarter worth $51,000. Finally, National Bank of Canada FI bought a new position in Esperion Therapeutics during the fourth quarter worth $61,000.

Esperion Therapeutics Company Profile (Get Rating)

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.

Read More